FOLH1 and neoplasm: A well-tolerated dose of 0.8 mg/kg × 2 resulted in significant antitumor effect against PSMA[+] PIP-PC3 cells and LNCaP with pathology showing almost complete elimination of tumor cells within 1–2 weeks following injection.